
Adverse Reaction Halts AstraZeneca Covid Trial
AstraZeneca has temporarily paused Phase 2/3 global clinical trials of the adenovirus-viral vector-based Covid-19 candidate it is developing for Oxford University. The Anglo-Swedish drugmaker initially cited “a serious suspected adverse reaction” in a participant without revealing details.









































